Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Odefsey

mHealth could be ‘the future’ of healthcare

EC says Europe is preparing for the mHealth revolution

- PMLiVE

CURx buys rights to Gilead’s lung infection drug

Agrees deal for fosfomycin/tobramycin combination

- PMLiVE

A new option for people with HIV

ViiV Healthcare's dolutegravir could capture a significant share of the HIV market and may have blockbuster potential

- PMLiVE

Mylan to sell Gilead’s medicines in India

Includes HIV treatments Viread, Truvada and Stribild

- PMLiVE

ViiV wins European approval for Tivicay

HIV treatment licensed in combination with other anti-retroviral drugs

- PMLiVE

EU clears Gilead’s hepatitis C therapy Sovaldi

Region’s first all-oral treatment approved to treat the virus

- PMLiVE

FDA sets standard review for Gilead’s idelalisib in NHL

Comes despite accelerated review for drug’s use in chronic lymphocytic leukaemia

- PMLiVE

FDA clears Isentress formulation for infants with HIV

Merck's integrase inhibitor available for children as young as four weeks

- PMLiVE

Technology-enhanced HIV testing service triumphs

Dean Street at Home initiative wins PMEA's digital/social award

- PMLiVE

ViiV’s Tivicay for HIV on course for EU approval

More positive news for GSK, Pfizer and Shionogi joint venture

- PMLiVE

CHMP recommends Gilead’s sofosbuvir for hep C

Set to be first interferon-free treatment regime

- PMLiVE

Gilead’s sofosbuvir aces FDA advisory committee

On track for hepatitis C approval in US

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links